Short Interest in BioRestorative Therapies, Inc. (NASDAQ:BRTX) Rises By 2,211.5%

BioRestorative Therapies, Inc. (NASDAQ:BRTX) was the recipient of a large increase in short interest during the month of June. As of June 15th, there was short interest totalling 1,870,000 shares, an increase of 2,211.5% from the May 31st total of 80,900 shares. Approximately 34.0% of the shares of the stock are short sold. Based on an average daily trading volume, of 2,110,000 shares, the short-interest ratio is currently 0.9 days.

Analysts Set New Price Targets

Separately, Roth Mkm reiterated a “buy” rating and set a $15.00 price target on shares of BioRestorative Therapies in a report on Wednesday, June 12th.

Institutional Investors Weigh In On BioRestorative Therapies

A hedge fund recently bought a new stake in BioRestorative Therapies stock. StoneX Group Inc. purchased a new position in BioRestorative Therapies, Inc. (NASDAQ:BRTX) in the 1st quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The institutional investor purchased 34,850 shares of the company’s stock, valued at approximately $48,000. StoneX Group Inc. owned 0.51% of BioRestorative Therapies as of its most recent filing with the Securities and Exchange Commission. Hedge funds and other institutional investors own 69.38% of the company’s stock.

BioRestorative Therapies Price Performance

BioRestorative Therapies stock opened at $2.03 on Friday. The stock has a market cap of $13.74 million, a price-to-earnings ratio of -0.88 and a beta of 61.71. BioRestorative Therapies has a 1 year low of $1.03 and a 1 year high of $4.60. The firm has a 50-day moving average of $1.48 and a two-hundred day moving average of $1.53.

BioRestorative Therapies (NASDAQ:BRTX) last released its quarterly earnings data on Tuesday, June 11th. The company reported ($0.53) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.51) by ($0.02). The company had revenue of $0.04 million during the quarter, compared to analysts’ expectations of $0.03 million. BioRestorative Therapies had a negative net margin of 7,303.33% and a negative return on equity of 96.09%. Research analysts expect that BioRestorative Therapies will post -2.36 earnings per share for the current year.

About BioRestorative Therapies

BioRestorative Therapies, Inc, a life sciences company, focuses on the development of regenerative medicine products and therapies using cell and tissue protocols primarily involving adult stem cells. The company's two core developmental programs relate to the treatment of disc/spine disease and metabolic disorders.